Company profile
Evommune, Inc.
Pipeline2 assets
- EVO756EVO756 / MRGPRX2 / Oral small-molecule antagonist / Chronic inflammatory diseasesChronic Spontaneous UrticariaPhase 2Atopic DermatitisPhase 2MigrainePhase 1
- EVO301EVO301 / IL-18 / Long-acting injectable SAFA-IL-18BP fusion protein / Chronic inflammatory diseasesAtopic DermatitisPhase 2Ulcerative ColitisPhase 1
Latest news6 items
All newsEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Trial Start • Phase 2Trial initiation Thu, Jul 30, 2026, 8:00 AM EDT
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Trial Results • Phase 2Top-line results Mon, Jun 29, 2026, 8:30 AM EDT